<DOC>
	<DOCNO>NCT00906893</DOCNO>
	<brief_summary>Hypoxia recognize independent predictor clinical outcome oncology . PET use [ 18F ] -FMISO describe useful non invasive assessment hypoxia cancer . The use radiotracer brain tumour limit standard acquire quantify [ 18F ] -FMISO uptake . So need methodological evaluation PET tracer The purpose research define optimal parameter acquisition data exploitation quantify [ 18F ] -FMISO uptake predict clinical outcome glioblastoma . Low sensitivity radiation glioblastoma partly cause hypoxia . Hypoxia tumour predict tumour size . Detecting monitor tissue oxygenation great interest modify therapeutic strategy , include local dose escalation radiotherapy select chemotherapeutic agent well impact glioblastoma . PET appropriate radiotracers , especially [ 18F ] -FMISO , enable non-invasive assessment hypoxia . [ 18F ] -FMISO accumulate viable hypoxic cell . So , demonstrate PET use 18F-FMISO suitable localize quantify hypoxia . But n't optimal acquisition protocol standardize image quantification treatment . Thus , interpretation [ 18F ] -FMISO PET image predictive value [ 18F ] -FMISO SUV ( Standardized Uptake Value ) remain unclear explain need methodological approach .</brief_summary>
	<brief_title>Evaluation 18F-FMISO Non Operated Glioblastoma</brief_title>
	<detailed_description>Hypoxia one bad prognostic factor clinical outcome glioblastoma . Today , well admit hypoxia heterogeneous , variable within different tumour type vary spatially temporally . Hypoxia induce proteomic gene expression change lead increase angiogenesis , invasion metastasis . So hypoxic fraction solid tumour reduces sensitivity conventional treatment modality , modulate therapeutic response ionize radiation certain chemotherapeutic agent . This particularly important glioblastoma . Hypoxic cell solid tumour could influence local failure follow radiotherapy associate malignant progression , loco regional spread distant metastases represent increase probability recurrence . Thus , non-invasive determination monitor oxygenation status tumours importance classify patient ' outcome modify therapeutic strategy tumour . Actually oxygenation status individual tumour assess routinely . Numerous different approach use identify hypoxia tumour . Eppendorf oxygen probe measurement ( pO2 histography ) may consider 'gold standard ' hypoxia human malignancy . However , invasive method confine superficial , well accessible tumour require many measure . PET use [ 18F ] Fluoro-deoxyglucose ( [ 18F ] -FDG ) , allow non-invasive image glucose metabolism take grow place cancer staging , [ 18F ] -FDG ca n't assess correctly oxygenation status tumour suitable brain tumor . PET appropriate radiotracers enable non-invasive assessment presence distribution hypoxia tumour . Nitroimidazoles class electron affinic molecule show accumulate hypoxic cell culture vivo . [ 18F ] -FMISO frequently employ tracer ; intracellular retention dependent oxygen concentration . Consequently [ 18F ] -FMISO use non-invasive technique detection hypoxia human . Different author demonstrate suitable localize quantify hypoxia . Thus , [ 18F ] -FMISO PET study evaluate prognosis predict treatment response . However , investigator report unclear correlation Eppendorf measurement standardize uptake value ( SUV ) . This observation may explain structural complexity hypoxic tumour tissue . Nevertheless , need standardized procedure acquire quantify [ 18F ] -FMISO uptake . Actually use tracer limit clinic academic study include small population patient suffer heterogeneity technical procedure . The aim study determine optimal acquisition protocol treatment parameter enable describe [ 18F ] -FMISO uptake glioblastoma know hardly influenced hypoxia . Then , validate [ 18F ] -FMISO-PET prognostic maker recurrence . We introduce pretherapy [ 18F ] -FMISO PET-CT treatment planning patient suffer different newly diagnose glioblastoma eligible radical treatment curative intent , consist conformational radiotherapy chemotherapy . [ 18F ] -FMISO PET-CT result take account patient management . We test different acquisition protocol use wild panel quantification parameter issue publish study original one develop team enable describe [ 18F ] -FMISO uptake . Patients follow clinically para-clinically one year end treatment accord edited recommendation tumour type grade analyze outcome ( failure define persistent disease primary site , progression disease , locoregional relapse complete response distant metastasis ) . Thus able measure failure free survival determine overall survival .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Patients 18 Patients malignant tumour glioblastoma propose radical treatment consist conformational radiotherapy and/or chemotherapy Signed informed consent Patients ca n't undergo radiotherapy chemotherapy Patients distant metastasis know inclusion except renal cancer patient metastasis include Patients suffer second cancer treat radiotherapy tumour site . Pregnant breast feed woman , woman age procreate without contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>[ 18F ] -FMISO uptake</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Hypoxia</keyword>
	<keyword>tumour</keyword>
</DOC>